The meta-analysis including 15 studies involving 2,765 patients with transthyretin amyloid cardiomyopathy suggested that the individuals who have undergone tafamidis treatment showed a significant positive influence on the lower risk of all-cause death or heart transplantation (RR: 0.44; 95% CI: 0.31–0.65; P = 0.00004) and composite endpoint (all-cause death, heart failure exacerbations, hospitalizations, heart transplant, and heart assist device implantation) (RR: 0.57; 95% CI: 0.42–0.77; P = 0.0003) compared to patients who have not undergone tafamidis treatment (Wang J. et al., 2023). Here, TTR is linked to heart failure.